Jump to section
BIOS Health's are on a mission to improve people's quality of life with neural engineering.
BIOS is unlocking the potential of the nervous system in treating chronic disease by using AI-powered neural interfaces that can automatically read and write neural signals.
The challenge in this field is how to collect and process large amounts of neural data and then accurately interpret the neural signals, which are incredibly noisy, continuously changing and travel throughout the body at incredible speed. In other words, a job best suited to machines underpinned by machine learning/AI.
BIOS’ neural code is built on the world’s largest proprietary neural data set and is already in use clinically to enhance data from wearables used in remote chronic disease care. This holds the key to new treatments for conditions including hypertension, diabetes, and rheumatoid arthritis, and in the future even diseases of the brain itself such as Parkinson’s or Alzheimer’s.
The plan is for BIOS to develop some products and treatments of its own, but also to partner with various companies and organisations. The premise is that the company can focus on the core interface and related AI, while the eventual applications can be as wide and vertical as advancements and interest allows.
Kirsty
Company Specialist at Welcome to the Jungle
Jun 2023
$20m
EARLY VC
Dec 2018
$4.5m
SEED
This company has top investors
Emil Hewage
(CEO)Former University of Cambridge PhD researcher specialised in computational neuroscience and machine learning, has held leadership and technology positions in deep tech startups.
Oliver Armitage
(CSO)PhD in biointerfaces and tissue engineering.